Nephro Care India Ltd

As of 07-Nov, Nephro Care India Ltd's stock price is 128.00, down 0.43%, and is trading below all key moving averages, indicating a bearish trend. Despite a significant year-to-date decline of 30.43%, there has been an increase in investor participation, with delivery volume up 85.67%.

As of 03-Nov, Nephro Care India Ltd is priced at 134.90, down 1.03%, and has underperformed its sector by 2.41%. The stock is in a bearish trend, trading below all major moving averages, with significant year-to-date losses of 26.68% and a 47.43% decline over the past year, despite increased investor participation.

As of 24-Sep, Nephro Care India Ltd is priced at 142.65, with a recent slight increase but significant declines of 18.06% over the past month and 22.47% year-to-date. The stock is underperforming compared to the Sensex, indicating a challenging outlook due to declining investor interest.

As of 23-Sep, Nephro Care India Ltd's stock price is at 142.15, down 0.77%, and has significantly underperformed its sector and the broader market, with a year-to-date decline of 22.74%. The stock shows mixed signals in trading averages and decreased investor participation, contributing to negative sentiment.

As of 22-Sep, Nephro Care India Ltd's stock price is at 143.25, down 2.58%, and has underperformed its sector by 2.15%. The stock has seen a significant decline in investor participation and is below several key moving averages, indicating a bearish trend, with a year-to-date drop of 22.15% compared to a positive market performance.

As of 19-Sep, Nephro Care India Ltd's stock price is 147.05, down 0.91%, and has significantly underperformed its sector and the Sensex over various time frames. Despite increased trading interest, the stock has declined 20.08% year-to-date and 43.87% over the past year, indicating a challenging market environment.

As of 18-September, Nephro Care India Ltd's stock price is 148.40, down 2.21%, with a year-to-date decline of 19.35% and a significant 43.46% drop over the past year. Despite recent underperformance compared to the Sensex, there is increased investor interest indicated by an 8.7% rise in delivery volume.

As of 17-Sep, Nephro Care India Ltd's stock price is 151.75, down 0.75%. The stock has underperformed its sector and the broader market, with a year-to-date decline of 17.53% and a significant drop of 42.94% over the past year.

As of 16-Sep, Nephro Care India Ltd's stock price is 152.90, down 3.65%, with a significant weekly decline of 8.09% and a year-to-date drop of 16.90%. The stock is underperforming compared to the broader market, as indicated by its negative year-on-year return of -41.72%.

As of 15-Sep, Nephro Care India Ltd's stock price is at 158.70, down 3.23%, with a significant drop in delivery volume and negative returns over the past week and year. The stock has underperformed compared to the benchmark Sensex, which has gained 1.20% over the past week.

As of 12-Sep, Nephro Care India Ltd's stock price is 164.00, with a slight increase of 0.09%. The stock has performed well recently but has declined significantly year-to-date and over the past year, lagging behind the benchmark Sensex.

As of September 11, 2025, Nephro Care is considered expensive with a PE ratio of 74.28 and remains overvalued compared to peers, having underperformed the Sensex with a return of -35.06% over the past year.

As of 11-Sep, Nephro Care India Ltd's stock price is at 163.85, down 0.09%. The stock has underperformed recently, with a year-to-date decline of 10.95% and a significant drop of 35.06% over the past year, indicating challenges in maintaining investor interest.

As of 10-Sep, Nephro Care India Ltd's stock price is at 164.00, down 1.41% today and 10.87% year-to-date, with a significant 36.91% decline over the past year. Despite recent underperformance compared to the benchmark Sensex, there has been increased investor interest indicated by a 37.2% rise in delivery volume.

As of September 9, 2025, Nephro Care is considered very expensive and overvalued with a PE ratio of 77.45 and an EV to EBITDA of 44.51, significantly higher than its peers, while its stock has declined by 36.54% over the past year.

As of 09-Sep, Nephro Care India Ltd is priced at 166.35, down 0.36%, and has underperformed its sector and the benchmark Sensex. Despite a 19.59% increase over the past month, the stock has declined 9.59% year-to-date and 36.54% over the past year, indicating a challenging environment with reduced investor participation.

As of 08-Sep, Nephro Care India Ltd is currently priced at 166.95, reflecting a recent upward trend with a 6.4 increase. Despite a year-to-date return of -9.27%, the stock has shown strong short-term performance and increased investor interest, suggesting a potential recovery phase.

As of 05-Sep, Nephro Care India Ltd's stock price is 160.55, down 5.0%, and has underperformed its sector by 3.89%. Despite a recent positive return of 3.55% over the past week, it has a year-to-date decline of 12.74% and a one-year drop of 42.35%, indicating ongoing challenges in attracting investor confidence.

As of September 4, 2025, Nephro Care is considered overvalued with a valuation grade of expensive, reflected by a PE ratio of 76.54 and an EV to EBITDA of 43.95, significantly higher than its peers, despite a recent positive stock return of 21.58% over the past month and a year-long decline of 37.64%.